New combo therapy for bladder cancer passes first safety test?
NCT ID NCT06586255
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing whether it is safe to give immunotherapy (nivolumab) together with radiation therapy after bladder cancer surgery. The study will enroll 10 people who have had their bladder removed. The main goal is to see if this combination causes serious side effects in the pelvic area. If it proves safe, it could lead to larger studies to see if it helps prevent cancer from returning.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab (immunotherapy) plus radiation therapy
What this could lead to
If safe, this combination could become a new treatment option to help prevent bladder cancer from coming back after surgery.
What could go wrong
This is a very early Phase I trial with only 10 people, so it is mainly checking safety, not effectiveness. There is a risk of side effects from the radiation and immunotherapy combination.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••